CANCER BIOMARKERS MARKET ANALYSIS

Cancer Biomarkers Market Size and Trends

Global cancer biomarkers market is estimated to be valued at USD 28.90 Bn in 2025 and is expected to reach USD 67.62 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.9% from 2025 to 2032.

To learn more about this report, Request sample copy

Advancements in precision medicine and personalized cancer treatment boosts demand for cancer biomarkers. The ability of biomarkers to detect cancer at its earliest stages, guide therapeutic options, and monitor the effectiveness of treatment is boosting its adoption across the healthcare industry. Biomarker tools that improve diagnosis and help clinicians develop targeted therapies tailored to an individual patient's tumor characteristics are most widely used in clinical practice. This shift towards precision medicine and individualized care based on a patient's molecular profile is propelling the cancer biomarkers market growth.

High prevalence and incidence of cancer

Rising prevalence of cancer is expected to drive the market growth over the forecast period. Breast cancer is the second most common type of cancer in the U.S., after skin cancer. Breast cancer can occur both, in men and women. However, it is mostly found among females and the male occurrence of breast cancer is very rare. For instance, according to the data provided by the Breastcancer.org in March 2022, an estimated 287,850 new cases of invasive breast cancer were diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer in 2022.